Press release content from PR Newswire. The AP news staff was not involved in its creation. Caprion-HistoGeneX Expands its Histological Biomarker Franchise by Joining Forces with Mosaic Laboratories January 12, 2021 GMT MONTREAL, Jan. 12, 2021 /PRNewswire/ - Caprion-HistoGeneX, a leading global contract research laboratory services provider backed by Arsenal Capital Partners (“Arsenal”), announced today the acquisition of Mosaic Laboratories LLC (“Mosaic”), a California-based company offering histology and immunohistochemistry services to global pharmaceutical clients. The addition of Mosaic further strengthens the North American base for Caprion-HistoGeneX’s histopathology assay development and deployment, expands the volume of pathology services and consolidates the company’s position as a world-leading service provider of histopathology biomarker analysis for global clinical trials.